Pharmacology

Richard Weinshilboum, M.D. studies pharmacogenomics — the role of inheritance and individual variation in DNA sequence or structure in drug response. The goal is to develop safer and more effective drug therapy to treat diseases that range from cancer to depression. Dr. Weinshilboum's research program utilizes genomic techniques that include genome-wide association studies (GWAS) and "next-generation" whole genome DNA sequencing using samples from large numbers of patients treated with a specific anticancer or antidepressant drug. Sophisticated cell-based functional genomic techniques are used to determine mechanisms responsible for variation in drug response phenotypes. This approach has already succeeded in the discovery and functional/mechanistic pursuit of novel, unanticipated genes that influence response to a series of drugs used to treat childhood leukemia and breast cancer. Dr. Weinshilboum's research has been continuously funded for decades by the National Institutes of Health and other Foundation funding mechanisms.

Nephrology and Hypertension Research Center for Clinical and Translational Science (CCaTS) Epidemiology and Genetics of Lung Cancer Research Program Experimental Therapeutics Program Women's Health Research Center Molecular Pharmacology and Experimental Therapeutics Research Mayo Clinic Cancer Center — Research Center for Individualized Medicine Pharmacogenomics - Richard M. Weinshilboum Aging: Robert and Arlene Kogod Center on Aging Women's Cancer Program

he research of Liewei Wang, M.D., Ph.D., is focused on pharmacogenomics, a critical component of individualized medicine that studies the role of inheritance in variation in drug response. Patients treated with the same dose or regimen of a drug can display different responses, ranging from lack of efficacy to severe toxicity. Dr. Wang's laboratory uses various high-throughput "omics" tools, including genomics, transcriptomics and metabolomics, to identify biomarkers that can help predict clinical response. At the same time, her lab uses various models, including cells, patient-derived xenografts and patient samples, to validate and understand the biology underlying these biomarkers.

Molecular Pharmacology and Experimental Therapeutics Research Pharmacogenomics and Drug Targets - Liewei Wang Center for Individualized Medicine Epidemiology and Genetics of Lung Cancer Research Program Experimental Therapeutics Program Women's Health Research Center Mayo Clinic Cancer Center — Research Women's Cancer Program

Shirley earned her M.S. in Pharmacology at the University of São Paulo in 1993. From 1994-1996, she worked as a researcher for the Japanese Ministry of Education in the Department of Pharmacology at the University of Kitasato in Tokyo. She has been an instructor in Pharmacology since 1997 and a researcher at the Medical School at the University of São Paulo (Faculdade de Medicina /Universidade de São Paulo). Shirley has been teaching undergraduate Pharmacology classes within Healthcare courses under the theme ‘Education to Prevent the Misuse of Drugs’.Her assistance is requested whenever there is difficulty associated with the pharmacological treatment in any given sector within different hospitals. Through research projects registered with the Ministry of Health, Shirley accesses and analyzes medical records to propose pharmacological care to complement patients’ treatments and minimize risks. Shirley has assisted in research with drugs in the Intensive Care Unit, Urgent Care, sedation in oncology, and in Psychiatry, Geriatrics and Pediatrics departments

Pharmacology,Neuro Pharmacology.

Dr. Krishna is currently Professor and Director of Pharmacology at the College of Osteopathic Medicine, Touro University in Nevada. He obtained a Bachelor of Science (First Class Honors) in Pharmacology and Physiology and a Doctor of Philosophy, Medicine (OB/GYN/Pharmacology) from Monash University in Australia. Dr. Krishna also teaches for the Step 1 USMLE and COMLEX reviews for Kaplan Medical throughout the United States and in UAE, Europe, Saudi Arabia, India, Mexico and the Caribbean. He has been teaching online for Kaplan University for over 7 years and is the contributing author for Kaplan Medical’s Pharmacology Review Book. He has contributed to numerous publications and is a member of a number of organizations including Fellow-American College of Clinical Pharmacology.

Neonatal Pharmacology,

Prof. Dr. Alireza Heidari, Ph.D., D.Sc. is a Full Professor and Academic Tenure of Chemistry at California South University (CSU), Irvine, California, USA. He has got his Ph.D. and D.Sc. degrees from California South University (CSU), Irvine, California, USA. Furthermore, he has double postdocs in Project Management, Oncology, Human Cancer Tissues and Synchrotron Radiation from Monash University, Melbourne, Victoria, Australia and also in Nanochemistry and Modern Molecular Electronic–Structure Computations Theory from California South University (CSU), Irvine, California, USA. His research interests include Biophysical Chemistry, Biomolecular Spectroscopy, Quantum Chemistry, Nanochemistry, Modern Electronic Structure Computations, Theoretical Chemistry, Mathematical Chemistry, Computational Chemistry, Vibrational Spectroscopy, Molecular Modelling, Ab initio & Density Functional Methods, Molecular Structure, Biochemistry, Molecular Simulation, Pharmaceutical Chemistry, Medicinal Chemistry, Oncology,

Molecular Dynamics, Biosensors, Biomarkers, Molecular Diagnostics, Numerical Chemistry, Nucleic Acids, DNA/RNA Monitoring, DNA/RNA Hypermethylation & Hypomethylation, Human Cancer Tissues, Human Cancer Cells, Tumors, Cancer Tissues, Cancer Cells, etc.

Amr Amin is a Professor of Cell & Molecular Biology and a graduate faculty at UAE University. He earned his PhD in Cell & Developmental Biology from University of Illinois at Chicago and received a postdoctoral training in Molecular Genetics at University of Pennsylvania School of Medicine. After joining UAEU, Dr. Amin’s focus was redirected to the field of preventive medicine. His lab is interested in natural product-based protection against cancer. Most recently, his lab has been employing non-invasive approaches and nanoparticles to learn more about the molecular aspects of chemoprevention particularly against liver cancer. He published many research articles, reviews and book chapters in reputable journals. He also serves on the editorial boards and as a reviewer of many international journals. Dr. Amin is also the recipient of many national and international awards.

Amr Amin research interests focus biology and chemoprevention of cancer, preclinical studies, and novel plant-based anticancer drugs.

Ming Lei, Ph.D., is director of the Division for Research Capacity Building. He oversees the Institute’s capacity-building programs, which include the Institutional Development Award (IDeA), Support of Competitive Research (SCORE), and Native American Research Centers for Health (NARCH), as well as the Science Education Partnerships Awards (SEPA).

Transverse cardiac slicing and optical imaging for analysis of transmural gradients in membrane potential and Ca2+ transients in murine heart.

After completion of his postdoctoral training at University of Texas MD Anderson Cancer Center, Dr. Gautam Sethi joined Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore in 2008 as an Assistant Professor and was promoted to Associate Professor in 2015. The focus of his research over the past few years has been to elucidate the mechanism (s) of activation of oncogenic transcription factors such as NF-kB/STAT3 by carcinogens and inflammatory agents and the identification of novel inhibitors of these proteins for prevention of and therapy for cancer. The findings of his research work have so far resulted in more than two hundred and fifty scientific publications in high impact factor peer reviewed journals (with h index = 74) and several international awards. He currently serves as an Academic Editor for PLOS, editorial board member of Cancer Letters, Scientific Reports, Pharmacological Research, World Journal of Pharmacology, BMC Cancer, Frontiers in Pharmacology, Frontiers in Oncology, International Journal of Biological Sciences, Journal of Functional Foods, Journal of Natural Products in Cancer Prevention and Therapy, and ad-hoc reviewer for several other prestigious international journals.

The focus of his research over the past few years has been to elucidate the mechanism (s) of activation of transcription factors NF-κB and STAT3 by carcinogens and inflammatory agents and the identification of novel inhibitors of NF-κB and STAT3 for prevention of and therapy for cancer. From natural sources, his group has identified numerous small molecules that can suppress NF-κB and STAT3 activation and inhibit TNF/IL-6 signaling. Thus, these agents have potential treatment properties for numerous inflammatory diseases, including cancer and are not toxic. Moreover, the results his research work have so far resulted in more than hundred scientific publications in high impact factor peer reviewed journals and several international research awards.